In a phase 1/2 study, once-daily gilteritinib administered as a single agent resulted in high response rates and improved overall survival in FLT3 mutation-positive patients with relapsed/refractory (R/R) AML [21]. Here, FLT3 is linked to acute myeloid leukemia.